PMID- 26722203
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160101
LR  - 20181113
IS  - 0972-2068 (Print)
IS  - 0973-9793 (Electronic)
IS  - 0973-9793 (Linking)
VI  - 77
IP  - 5
DP  - 2015 Oct
TI  - Pancreatic Neuroendocrine Tumors: an Update.
PG  - 395-402
LID - 10.1007/s12262-015-1360-2 [doi]
AB  - Pancreatic neuroendocrine tumors (pNETs) are rare and comprise only 1-2 % of all 
      pancreatic neoplastic disease. Although the majority of these tumors are sporadic 
      (90 %), pNETs can arise in the setting of several different hereditary genetic 
      syndromes, most commonly multiple endocrine neoplasia type 1 (MEN1). The 
      presentation of pNETs varies widely, with over 60 % having malignant distant 
      disease at the time of initial diagnosis involving the liver or other distant 
      sites. Functioning pNETs represent approximately 10 % of all pNETs, secrete a 
      variety of peptide hormones, and are responsible for several clinical syndromes 
      caused by profound hormonal derangement. Surgery remains the cornerstone of 
      therapy and the only curative approach. It should be pursued for localized 
      disease and for metastatic lesions amenable to resection. Multimodality 
      therapies, including liver-directed therapies and medical therapy, are gaining 
      increasing favor in the treatment of advanced pNETs. Their utility is multifold 
      and spans from ameliorating symptoms of hormonal excess (functional pNETs) to 
      controlling the local and systemic disease burden (non-functional pNETs). The 
      recent introduction of target molecular therapy has promising results especially 
      for the treatment of progressive well-differentiated G1/G2 tumor. In this review, 
      we summarize the current knowledge and give an update on recent advancements made 
      in the therapeutic strategies for pNETs.
FAU - Paniccia, Alessandro
AU  - Paniccia A
AD  - Division of GI, Tumor and Endocrine Surgery, Department of Surgery, University of 
      Colorado at Denver, Aurora, CO USA.
FAU - Edil, Barish H
AU  - Edil BH
AD  - Division of GI, Tumor and Endocrine Surgery, Department of Surgery, University of 
      Colorado at Denver, Aurora, CO USA.
FAU - Schulick, Richard D
AU  - Schulick RD
AD  - Division of GI, Tumor and Endocrine Surgery, Department of Surgery, University of 
      Colorado at Denver, Aurora, CO USA ; Department of Surgery, University of 
      Colorado Anschutz Medical Campus, 12631 E. 17th Avenue, C-305, Aurora, CO 80045 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20151013
PL  - India
TA  - Indian J Surg
JT  - The Indian journal of surgery
JID - 0373026
PMC - PMC4689705
OTO - NOTNLM
OT  - Neuroendocrine tumor
OT  - Pancreatic cancer
OT  - pNET
EDAT- 2016/01/02 06:00
MHDA- 2016/01/02 06:01
PMCR- 2016/10/01
CRDT- 2016/01/02 06:00
PHST- 2015/09/24 00:00 [received]
PHST- 2015/09/30 00:00 [accepted]
PHST- 2016/01/02 06:00 [entrez]
PHST- 2016/01/02 06:00 [pubmed]
PHST- 2016/01/02 06:01 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - 1360 [pii]
AID - 10.1007/s12262-015-1360-2 [doi]
PST - ppublish
SO  - Indian J Surg. 2015 Oct;77(5):395-402. doi: 10.1007/s12262-015-1360-2. Epub 2015 
      Oct 13.